156 related articles for article (PubMed ID: 17377809)
21. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
[TBL] [Abstract][Full Text] [Related]
22. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
23. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
[TBL] [Abstract][Full Text] [Related]
24. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
25. Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.
Woenckhaus J; Steger K; Werner E; Fenic I; Gamerdinger U; Dreyer T; Stahl U
J Pathol; 2002 Nov; 198(3):335-42. PubMed ID: 12375266
[TBL] [Abstract][Full Text] [Related]
26. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
27. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
28. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
Kolasa IK; Rembiszewska A; Felisiak A; Ziolkowska-Seta I; Murawska M; Moes J; Timorek A; Dansonka-Mieszkowska A; Kupryjanczyk J
Cancer Biol Ther; 2009 Jan; 8(1):21-6. PubMed ID: 19029838
[TBL] [Abstract][Full Text] [Related]
29. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma.
Psyrri A; Papageorgiou S; Liakata E; Scorilas A; Rontogianni D; Kontos CK; Argyriou P; Pectasides D; Harhalakis N; Pappa V; Kolialexi A; Economopoulou C; Kontsioti F; Maratou E; Dimitriadis G; Economopoulou P; Economopoulos T
Clin Cancer Res; 2009 Sep; 15(18):5724-32. PubMed ID: 19723646
[TBL] [Abstract][Full Text] [Related]
30. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.
Wu G; Mambo E; Guo Z; Hu S; Huang X; Gollin SM; Trink B; Ladenson PW; Sidransky D; Xing M
J Clin Endocrinol Metab; 2005 Aug; 90(8):4688-93. PubMed ID: 15928251
[TBL] [Abstract][Full Text] [Related]
31. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
[TBL] [Abstract][Full Text] [Related]
32. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome.
Huang J; Zhang L; Greshock J; Colligon TA; Wang Y; Ward R; Katsaros D; Lassus H; Butzow R; Godwin AK; Testa JR; Nathanson KL; Gimotty PA; Coukos G; Weber BL; Degenhardt Y
Genes Chromosomes Cancer; 2011 Aug; 50(8):606-18. PubMed ID: 21563232
[TBL] [Abstract][Full Text] [Related]
33. Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA.
Zhang W; Hubbard A; Baca-Parkinson L; Stanislaw S; Vladich F; Robida MD; Grille JG; Maxwell D; Tsao TS; Carroll W; Gardner T; Clements J; Singh S; Tang L
J Mol Diagn; 2015 Sep; 17(5):496-504. PubMed ID: 26163898
[TBL] [Abstract][Full Text] [Related]
34. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
Jiang G; Huang Z; Zhang S; Wang L
Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
[TBL] [Abstract][Full Text] [Related]
36. Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma.
Huang Y; Hua K; Zhou X; Jin H; Chen X; Lu X; Yu Y; Zha X; Feng Y
Cell Res; 2008 Jul; 18(7):780-91. PubMed ID: 18574502
[TBL] [Abstract][Full Text] [Related]
37. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
38. Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
El-Habr EA; Tsiorva P; Theodorou M; Levidou G; Korkolopoulou P; Vretakos G; Petraki L; Michalopoulos NV; Patsouris E; Saetta AA
Clin Neuropathol; 2010; 29(4):239-45. PubMed ID: 20569675
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
40. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
